Jazz Pharmaceuticals plc - SHS USD (JAZZ)

Historical Portfolio Holders from Q1 2014 to Q3 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Equity / SHS USD
Shares, excl. options Q2 2024
57.4M
Holdings value Q2 2024
$6.13B
Value change Q2 2024
-$48.3M
Grand Portfolio weight change Q2 2024
0%
Number of holders
444
Number of buys Q2 2024
53
Number of sells Q2 2024
-53
Average buys Q2 2024 %
+0.002%
Average sells Q2 2024 %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 3.12M $348M +$43.6M $111.41 112
2024 Q2 57.4M $6.13B -$48.3M $106.73 446
2024 Q1 57.8M $6.96B +$219M $120.42 471
2023 Q4 56.1M $6.9B -$32.8M $123.00 488
2023 Q3 55.4M $7.17B -$23.4M $129.44 475
2023 Q2 55.6M $6.9B -$39.2M $123.97 459
2023 Q1 55.7M $8.15B -$2.02M $146.33 458
2022 Q4 55.9M $8.91B -$97.4M $159.31 474
2022 Q3 56.7M $7.55B -$101M $133.29 442
2022 Q2 57.1M $8.9B +$137M $156.01 444
2022 Q1 56.6M $8.81B -$113M $155.67 435
2021 Q4 57.5M $7.33B +$20.4M $127.40 421
2021 Q3 56.7M $7.39B -$120M $130.21 421
2021 Q2 57M $10.1B +$779M $177.64 477
2021 Q1 53M $8.71B +$29.5M $164.37 440
2020 Q4 52.6M $8.68B -$295M $165.05 424
2020 Q3 54.5M $7.77B +$372M $142.59 381
2020 Q2 52.1M $5.74B +$273M $110.34 375
2020 Q1 49.8M $4.96B -$262M $99.74 394
2019 Q4 51.8M $7.74B +$162M $149.28 436
2019 Q3 50.9M $6.53B +$95.6M $128.14 398
2019 Q2 50.1M $7.13B +$207M $142.56 407
2019 Q1 51.4M $7.34B -$212M $142.95 417
2018 Q4 52.9M $6.55B -$427M $123.96 409
2018 Q3 55.4M $9.3B -$147M $168.13 398
2018 Q2 56.2M $9.67B +$436M $172.30 379
2018 Q1 53.7M $8.09B -$76.2M $150.99 323
2017 Q4 54.2M $7.3B -$66.7M $134.65 319
2017 Q3 54.6M $8B +$210M $146.25 298
2017 Q2 53.1M $8.26B +$381M $155.50 312
2017 Q1 51.9M $7.53B +$546M $145.13 301
2016 Q4 51.9M $5.66B -$184M $109.03 287
2016 Q3 52.2M $6.34B -$44.3M $121.48 315
2016 Q2 53.9M $7.61B -$56.6M $141.31 353
2016 Q1 54.5M $7.11B -$237M $130.55 329
2015 Q4 56.3M $7.91B -$26.5M $140.56 340
2015 Q3 55.3M $7.35B +$36.6M $132.81 353
2015 Q2 56M $9.86B +$576M $176.07 367
2015 Q1 50.9M $8.79B -$344M $172.79 350
2014 Q4 54.4M $8.91B +$176M $163.73 353
2014 Q3 53.2M $8.54B +$343M $160.56 324
2014 Q2 50.5M $7.42B +$48.1M $147.01 304
2014 Q1 50.5M $7B +$314M $138.68 310